For example, KRAS mutations (72) can impair the efficacy of anti-EGFR treatment in colorectal cancer, and gemcitabine resistance is linked to TP53 mutations (73), CDKN2A inactivation (74), and SMAD4 loss (75). This evidence concerns the gene KRAS and colorectal cancer.